Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

324.71 +0.48 (+0.15%)
Official Closing Price Updated: 7:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
Exposures COVID-19
Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows
Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's... 
Via Benzinga
How This Pharma Company Can Benefit From Its Competitors
Delays in FDA approval for Incyte could spell good news for Sanofi. 
Via The Motley Fool
Exposures Product Safety
Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion
Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics ​​​worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong... 
Via Talk Markets
2 Stocks That Could Be Winners in Alzheimer's Disease Along With Biogen
One is Biogen's partner. The other is a potential rival. 
Via The Motley Fool
4 Top Stock Trades for Monday: MSFT, TWLO, LLY, GE
Microsoft, Twilio, Eli Lilly and General Electric were our top stock trades for Monday. Let's look at how the charts are setting up now. 
Via InvestorPlace
Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC
Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to treat COVID-19 and other... 
Via Benzinga
Exposures COVID-19
Market Briefing For Thursday, Jun. 17
Vulnerability is bifurcated, just like sector rotation indicated all year thus far. It is typical to see risk increased amidst superficial optimism at high S&P levels, but that's not really what moved... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Cramer Shares His Thoughts On Vertex Pharma, Snap And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said it's a good opportunity to pick up some Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). The stock... 
Via Benzinga
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical... 
Via Benzinga
Where Eli Lilly Stands With Analysts
Within the last quarter, Eli Lilly (NYSE:LLY) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1 0 Somewhat... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Raymond James raised Nutrien Ltd. (NYSE: NTR) price target from $75 to $82. Nutrien shares fell 1.1% to trade at $63.05 on Tuesday. Credit Suisse lifted the price target on... 
Via Benzinga
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
The Latest Barron's Picks And Pans: DocuSign, UPS, Taiwan Semiconductor And More
The cover story in this weekend's Barron's examines how teenage traders are shaking up the market. Other featured articles discuss which drugmakers benefit from a new... 
Via Benzinga
Eli Lilly's Internal Probe Clears Its COVID-19 Drug Plant; Memo Says Company Did Not Make False Statements: Reuters
Eli Lilly and Co (NYSE: LLY) revealed last month that the U.S. Department of Justice (DOJ) issued a subpoena into its manufacturing facility in Branchburg, New... 
Via Benzinga
Topics Law Enforcement
Exposures COVID-19 Legal
8 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away... 
Via Benzinga
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
S&P 500 Hits Record High; Biogen Alzheimer's Drug, Tesla, Apple, RH, GameStop In Focus: Weekly Review
The S&P 500 hit a new high this week. The FDA OK'd a Biogen Alzheimer's drug. Tesla, Apple, RH, GameStop were in focus. 
Via Investor's Business Daily
Topics Stocks
Exposures Product Safety US Equities
Why Biogen, Lilly, and Prothena Stocks Soared This Week
The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (... 
Via Benzinga
5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing
Biogen Inc.'s (NASDAQ: BIIB) Alzheimer's treatment Aduhelm was approved by the FDA Monday, sending the company's shares up over 38%. The Biogen Analysts:... 
Via Benzinga
Exposures Product Safety
Biogen Snagged: Will Hefty Price Tag Hinder Alzheimer's Drug Use?
Biogen stock dipped Tuesday as analysts questioned how much use its potential blockbuster Alzheimer's treatment, Aduhelm, would ultimately secure. 
Via Investor's Business Daily
The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 7) Agios Pharmaceuticals, Inc... 
Via Benzinga
FDA surprise
The big news out of China is that its import purchases of copper and iron sagged last month because its export markets are far less strong than earlier this year. 
Via Talk Markets
Exposures Product Safety
Why Eli Lilly Stock Soared Today
Biogen's stunning win of FDA approval for aducanumab spurred investors' excitement about Lilly's prospects for its Alzheimer's disease candidate. 
Via The Motley Fool
Exposures Product Safety
Biogen Wins Landmark Alzheimer's Approval: 5 Things To Know About Aducanumab
The FDA approved Biogen's Alzheimer's treatment, aducanumab, on Monday — though Biogen stock remained halted into the long-awaited decision. 
Via Investor's Business Daily
Exposures Product Safety
Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor
Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to... 
Via Talk Markets
3 Dividend-Paying Pharmaceutical Stocks to Buy This Summer
The pharmaceutical industry has benefited from much investor attention amid the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
Ahead Of Judgement Day, FDA Faces Test with Biogen's Alzheimer's Drug Decision
U.S. regulators are slated to decide by Monday whether to approve Biogen Inc’s (NASDAQ: BIIB) much-talked-about Alzheimer’s disease drug, aducanumab.... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.